Free tool
FAERS Monitor: Nor-Qd
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017060 or its brand name (Nor-Qd, Norethindrone). Reports on generic versions are filed under their own applications.
Reports
3,155
Serious
1,626
52% of reports
Hospitalization
672
Death reported
50
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea251
- headache242
- off label use219
- fatigue198
- drug ineffective193
- pain170
- hot flush159
- abdominal pain151
- vaginal haemorrhage144
- diarrhoea141
- vomiting133
- arthralgia131
- anxiety115
- dizziness115
- dyspnoea115
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 8 |
| 2006 | 3 |
| 2007 | 10 |
| 2008 | 9 |
| 2009 | 38 |
| 2010 | 50 |
| 2011 | 90 |
| 2012 | 106 |
| 2013 | 105 |
| 2014 | 184 |
| 2015 | 213 |
| 2016 | 210 |
| 2017 | 147 |
| 2018 | 162 |
| 2019 | 138 |
| 2020 | 136 |
| 2021 | 193 |
| 2022 | 307 |
| 2023 | 310 |
| 2024 | 279 |
| 2025 | 250 |
| 2026 | 206 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,004 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vaginal haemorrhageSignal | 144 | 22.2 | 18.9 | 2,888 |
| hot flushSignal | 159 | 14.1 | 12.1 | 1,924 |
| abdominal painSignal | 151 | 4.3 | 3.7 | 387 |
| anxietySignal | 115 | 2.7 | 2.3 | 122 |
| headacheSignal | 242 | 2.6 | 2.3 | 238 |
| nauseaSignal | 251 | 2.1 | 1.9 | 152 |
| arthralgiaSignal | 131 | 2.1 | 1.8 | 76 |
| vomiting | 133 | 1.9 | 1.6 | 56 |
| pain | 170 | 1.8 | 1.6 | 67 |
| fatigue | 198 | 1.7 | 1.5 | 58 |
| off label use | 219 | 1.7 | 1.5 | 60 |
| dizziness | 115 | 1.5 | 1.3 | 22 |
| diarrhoea | 141 | 1.5 | 1.2 | 20 |
| dyspnoea | 115 | 1.4 | 1.1 | 11 |
| drug ineffective | 193 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.